Cardio-Oncology (Record no. 30130)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05596nam a22003497a 4500 |
| 001 - CONTROL NUMBER | |
| control field | 20250726140154.0 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | 20250726140154.0 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250726140715.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250726b |||||||| |||| 00| 0 eng d |
| 016 ## - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER | |
| Record control number | 20250726140154.0 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 978-3-030-97743-6 |
| International Standard Book Number | 978-3-030-97744-3 (eBook) |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2197-781X |
| International Standard Serial Number | 2197-7828 (electronic) |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | DDC |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 045 ## - TIME PERIOD OF CONTENT | |
| Time period code | 20250726140154.0 |
| Formatted 9999 B.C. through C.E. time period | 20250726140154.0 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Antonio Russo |
| 222 ## - KEY TITLE | |
| Key title | Common terms and phrases abnormalities acute coronary syndrome anthracycline anticancer therapy arrhythmias arterial associated with immune atezolizumab atrial fibrillation avelumab bevacizumab biomarkers BNP breast cancer cancer patients cancer therapy cardiac biomarkers cardiac dysfunction cardiac tamponade cardiac toxicity cardiac troponin cardio-oncology cardiomyopathy cardiotoxicity Cardiovasc cardiovascular events cardiovascular toxicity CheckMate chemotherapy Clin Oncol clinical CMR Coll Cardiol combination diagnosis durvalumab ECG echocardiogram echocardiography elevation endothelial Engl European Society evaluation Farmakis Fig first-line treatment G guidelines heart failure HR ICI-associated myocarditis ICI-related ICIs imaging immune checkpoint inhibitors immune-related adverse events immunosuppressive Immunother immunotherapy inflammatory ipilimumab irAEs Italy Lancet Oncol left ventricular lung cancer LVEF markers median PFS melanoma metastatic MSI-H myocardial infarction myocarditis natriuretic peptide nivolumab NSCLC Oncology open-label patients receiving patients treated pembrolizumab pericardial disease pericardial effusion phase randomized reported risk factors role Russo Society of Cardiology sunitinib symptoms systematic review T-cell thromboembolism tion trial troponin tumor University of Palermo vascular vasculitis |
| Qualifying information | Common terms and phrases abnormalities acute coronary syndrome anthracycline anticancer therapy arrhythmias arterial associated with immune atezolizumab atrial fibrillation avelumab bevacizumab biomarkers BNP breast cancer cancer patients cancer therapy cardiac biomarkers cardiac dysfunction cardiac tamponade cardiac toxicity cardiac troponin cardio-oncology cardiomyopathy cardiotoxicity Cardiovasc cardiovascular events cardiovascular toxicity CheckMate chemotherapy Clin Oncol clinical CMR Coll Cardiol combination diagnosis durvalumab ECG echocardiogram echocardiography elevation endothelial Engl European Society evaluation Farmakis Fig first-line treatment G guidelines heart failure HR ICI-associated myocarditis ICI-related ICIs imaging immune checkpoint inhibitors immune-related adverse events immunosuppressive Immunother immunotherapy inflammatory ipilimumab irAEs Italy Lancet Oncol left ventricular lung cancer LVEF markers median PFS melanoma metastatic MSI-H myocardial infarction myocarditis natriuretic peptide nivolumab NSCLC Oncology open-label patients receiving patients treated pembrolizumab pericardial disease pericardial effusion phase randomized reported risk factors role Russo Society of Cardiology sunitinib symptoms systematic review T-cell thromboembolism tion trial troponin tumor University of Palermo vascular vasculitis |
| 245 ## - TITLE STATEMENT | |
| Title | Cardio-Oncology |
| Remainder of title | Management of Toxicities in the Era of Immunotherapy |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Palermo, Italy | |
| Name of publisher, distributor, etc. | Springer Nature Switzerland AG | |
| Date of publication, distribution, etc. | 2022 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 127 Pages |
| Extent | Includes References and Index |
| 490 ## - SERIES STATEMENT | |
| Series statement | Current Clinical Pathology |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery. |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Cardiology, Internal medicine, Medical / Cardiology, Medical / Clinical Medicine, Medical / Internal Medicine, Medical / Oncology / General, Medical / Pathology, Oncology, Pathology, Cancer -- Immunotherapy, Cancer -- Immunotherapy -- Complications, Cardiovascular toxicology |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Dates associated with a name | Nicola Maurea |
| Dates associated with a name | Dimitrios Farmakis |
| Dates associated with a name | Antonio Giordano |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1007/978-3-030-97744-3 ">https://doi.org/10.1007/978-3-030-97744-3 </a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | E-BOOKS |
| Suppress in OPAC | |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Date acquired | Total checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 07/26/2025 | 20250726140154.0 | 07/26/2025 | 07/26/2025 | E-BOOKS |